English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

High grade/ grade-3 tumours (T1-HG/G3) with lamina propria invasion form the highest risk category of nonmuscle invasive bladder cancer (NMIBC) for progression to muscle invasive disease and cancer specific mortality[1]. The only treatment modality which can reduce the risk of progression is intravesical Bacillus Calmette Guerin (BCG) immunotherapy and the patient should indeed receive optimal BCG therapy-i.e.BCG induction with a six-week induction course followed by maintenance [2]. In Sri Lanka, T1-HG/G3 patients did not receive intravesical BCG due to non-availability during the study period (20002014).

ceylon medical journal/the ceylon medical journal

Clinical outcomes in a cohort of patients with T1 high grade urothelial bladder cancer not receiving intravesical bacillus Calmette-Guerin: a 15 year experience